13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Falls are a frequent and serious complication of Parkinson's disease and are related partly to an underlying cholinergic deficit that contributes to gait and cognitive dysfunction in these patients. Gait dysfunction can lead to an increased variability of gait from one step to another, raising the likelihood of falls. In the ReSPonD trial we aimed to assess whether ameliorating this cholinergic deficit with the acetylcholinesterase inhibitor rivastigmine would reduce gait variability.

          Related collections

          Author and article information

          Journal
          Lancet Neurol
          The Lancet. Neurology
          1474-4465
          1474-4422
          Mar 2016
          : 15
          : 3
          Affiliations
          [1 ] School of Social and Community Medicine, University of Bristol, Bristol, UK. Electronic address: emily.henderson@bristol.ac.uk.
          [2 ] Neuroscience Research Australia, University of New South Wales, Sydney, NSW, Australia.
          [3 ] Bristol Randomised Trials Collaboration, School of Social and Community Medicine, University of Bristol, Bristol, UK.
          [4 ] School of Psychology and Cardiff University Brain Research Imaging Centre (CUBRIC), Cardiff University, UK.
          [5 ] Neuroscience Research Australia, University of New South Wales, Sydney, NSW, Australia; Prince of Wales Clinical School, University of New South Wales, Sydney, NSW, Australia.
          [6 ] Bristol Institute of Clinical Neurosciences, University of Bristol, UK; Department of Neurology, Southmead Hospital, North Bristol NHS Trust, Bristol, UK.
          [7 ] School of Social and Community Medicine, University of Bristol, Bristol, UK.
          Article
          S1474-4422(15)00389-0
          10.1016/S1474-4422(15)00389-0
          26795874
          296e40cc-42a6-49d7-908e-014730b589b8
          Copyright © 2016 Henderson et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.
          History

          Comments

          Comment on this article